Frederic Thalheimer

Title: Frederic Thalheimer: Innovator in Targeted T Cell Transduction

Introduction

Frederic Thalheimer is a notable inventor based in Bergisch Gladbach, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of targeted therapies for T cell subsets.

Latest Patents

Thalheimer holds a patent for a "CD62L specific lentiviral vector particle for targeted transduction of T cell subsets." This invention provides a composition that includes a pseudotyped retroviral vector particle. The vector comprises an envelope protein with antigen-binding activity, which is a recombinant protein that does not interact with its original receptors. This innovative approach aims to enhance the specificity and efficacy of T cell targeting in therapeutic applications. He has 1 patent to his name.

Career Highlights

Frederic Thalheimer is currently associated with Miltenyi Biorec B V. Co., Kg, where he continues to advance his research and development efforts. His work focuses on improving the precision of immunotherapies, which are crucial in treating various diseases, including cancer.

Collaborations

Thalheimer collaborates with esteemed colleagues such as Thomas Schaser and Andrew Kaiser. Their combined expertise contributes to the innovative projects at Miltenyi Biorec B V. Co., Kg.

Conclusion

Frederic Thalheimer's contributions to biotechnology, particularly through his patent on targeted T cell transduction, highlight his role as an influential inventor in the field. His ongoing work promises to enhance therapeutic strategies for immune-related conditions.